secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001493152-23-039945
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences Q3 revenue $9.1M (+11% YoY); expects FY2023 revenue >$40M
-------------------------------------------------------------------------------

- Q3 net revenue $9.1M, up 11% from $8.2M; test volume up 11% YoY.
- Loss from continuing ops $(0.5)M vs $(1.3)M; adjusted EBITDA $0.4M vs $0.1M.
- Repaid $2.5M Comerica line of credit and $3M Terminal Payment to BroadOak; renegotiated long-term debt.
- Cash balance $5.0M at Sept 30, 2023; cash collections $9.8M vs $7.6M.
- Expects full-year 2023 revenue to exceed $40M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/0001493152-23-039945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223039945/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer